Erasca, Inc. (ERAS) vs Ligand Pharmaceuticals Incorporated (LGND)
- Erasca, Inc. ERAS 13.39 −9.95%
- Ligand Pharmaceuticals Incorporated LGND 295.54 −0.99%
Erasca, Inc. and Ligand Pharmaceuticals Incorporated are both Biotechnology companies. Ligand Pharmaceuticals Incorporated is the larger, with a market value of $6.0B against $5.2B — 1.1× the size. Erasca, Inc. has negative trailing earnings, so its P/E is not meaningful; Ligand Pharmaceuticals Incorporated trades at 29.5×. Ligand Pharmaceuticals Incorporated has the higher net margin (67.9% vs 0.00%) and the higher return on invested capital (8.19% vs −203.1%). Across the 14 metrics below, Ligand Pharmaceuticals Incorporated leads on 13 and Erasca, Inc. on 1.
Valuation
Profitability
| Metric | ERAS | LGND | Biotechnology median |
|---|---|---|---|
| Gross margin | 0.00% | 95.43% | 65.16% |
| Operating margin | 0.00% | 32.61% | 0.00% |
| Net margin | 0.00% | 67.88% | 0.00% |
| Free cash flow margin | 0.00% | 49.34% | 0.00% |
| Return on equity | (78.25%) | 21.96% | (56.36%) |
| Return on assets | (65.25%) | 12.58% | (48.04%) |
| Return on invested capital | (203.13%) | 8.19% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack